Revenio Group Oyj (Revenio) develops and manufactures health tech screening devices. The company primarily offers tonometers, which are used for diagnosing, screening and monitoring of various diseases, including glaucoma, asthma, and skin diseases. Revenio's product portfolio includes tonometers, imaging devices, and perimeters, serving healthcare professionals and eye care specialists, and also includes devices for detecting age-related eye diseases, which include glaucoma, diabetic retinopathy, and macular degeneration. The company's tonometers include the iCare IC100 for routine screenings, the iCare IC200 with 200-degree positional freedom for surgical or emergency use, and the iCare ST500 for slit lamp integration. The line also features the iCare HOME2 for patient self-monitoring at home, the iCare TONOVET Pro and Plus for veterinary diagnostics, and single-use iCare Probes to prevent cross-contamination.The company's imaging devices include the iCare EIDON range, which offers three automated models for wide-field retinal views with true color fidelity. It also includes the iCare DRSplus, a non-mydriatic fundus camera that uses confocal technology to capture high-quality retinal images through tiny 2–2.5 mm pupils and dense cataract opacities. The company's perimeters include the iCare COMPASS, an advanced diagnostic system that combines visual field testing with true-color confocal retinal imaging. This integrated approach drastically improves test repeatability compared to legacy industry standards, providing highly reliable data for tracking progressive eye conditions like glaucoma. The company offers software solutions that enhance clinical workflows and patient care pathways: iCare ILLUME and Oculo Software Solutions. iCare ILLUME combines AI screening with TrueColor Confocal fundus imaging to automatically detect early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma without requiring pupil dilation, while offering external referral capabilities through ILLUME Connect. Oculo is an Australian cloud-based platform that unifies clinical communication, telehealth, remote monitoring, and data analytics. Together, these complementary solutions optimize the efficiency of eye care professionals by bridging disconnected electronic health records, eliminating data silos, and enabling seamless, cost-effective collaboration across clinical teams. Revenio serves a diverse customer base, including ophthalmologists and optometrists. Its primary markets include the US, Europe, the Middle East, and Africa / Latin America / Canada, and Asia-Pacific, with products sold in nearly 100 countries through a comprehensive network of international strategic partners and distributors.

Revenio R&D initiatives are focused on shifting its product mix from standalone hardware to integrated, predictive, and cloud-connected eye care ecosystems. The company is prioritizing software innovation efforts to expand its deep-learning and artificial intelligence capabilities, particularly refining the iCare RETCAD AI screening platform for processing large patient volumes and supporting early clinical diagnostics for vision-threatening diseases. On the hardware side, the company successfully launched the iCare MAIA microperimeter and the cloud-based iCare ALTIUS eye health information management network in the United States. Additionally, the company is emphasizing sustainable engineering by designing all new products developed in 2025 to comply with the IEC 60601-1-9 environmentally conscious product design standard. The R&D unit(s) of Revenio are responsible for managing the company's research and development activities, focusing on software innovation, hardware development, and sustainable engineering practices. In FY2025, the company spent EUR11.6 million on its R&D activities, which amounted to 10.6% of the company's annual revenue.